Grayce Lima

Prof. Grayce Lima

UNIFOR
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
EFErika Freire
Erika Freire
CDCatarina Brasil D’alva
Catarina Brasil D’alva
MMMayara Ponte Madeira
Mayara Ponte Madeira
GLGrayce Lima
Grayce Lima
AMAna Paula Dias Rangel Montenegro
Ana Paula Dias Rangel Montenegro
B(Brazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO)
Brazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO)
Congenital Generalized Lipodystrophy (CGL) is a rare syndrome characterized by the almost total absence of subcutaneous adipose tissue due to the inability of storing lipid in adipocytes. Patients present generalized lack of subcutaneous fat and normal to low weight. They evolve with severe metabolic disorders, non-alcoholic fatty liver disease, early cardiac abnormalities, and infectious complications. Although low body weight is a known risk factor for osteoporosis, it has been reported that type 1 and 2 CGL have a tendency of high bone mineral density (BMD). In this review, we discuss the role of bone marrow tissue, adipokines, and insulin resistance in the setting of the normal to high BMD of CGL patients. Data bases from Pubmed and LILACS were searched, and 113 articles published until 10 April 2021 were obtained. Of these, 76 were excluded for not covering the review topic. A manual search for additional literature was performed using the bibliographies of the studies located. The elucidation of the mechanisms responsible for the increase in BMD in this unique model of insulin resistance may contribute to the understanding of the interrelationships between bone, muscle, and adipose tissue in a pathophysiological and therapeutic perspective.

7 November 2022 in 3 Biotech
Verified
Journal Article
Open access
PDF file
José Ednésio da Cruz FreireJosé Ednésio da Cruz Freire
José Ednésio da Cruz Freire
JJJosé Edvar Monteiro Júnior
José Edvar Monteiro Júnior
DPDaniel Pascoalino Pinheiro
Daniel Pascoalino Pinheiro
GLGrayce Lima
Grayce Lima
CACamila Lopes Do Amaral
Camila Lopes Do Amaral
Renan Magalhães Montenegro JuniorRenan Magalhães Montenegro Junior
Renan Magalhães Montenegro Junior
The current outbreak of COVID-19 cases worldwide has been responsible for a significant number of deaths, especially in hospitalized patients suffering from comorbidities, such as obesity, diabetes, hypertension. The disease not only has prompted an interest in the pathophysiology, but also it has propelled a massive race to find new anti-SARS-CoV-2 drugs. In this scenario, known drugs commonly used to treat other diseases have been suggested as alternative or complementary therapeutics. Herein we propose the use of sitagliptin, an inhibitor of dipeptidyl peptidase-4 (DPP4) used to treat type-II diabetes, as an agent to block and inhibit the activity of two proteases, 3CLpro and PLpro, related to the processing of SARS-CoV-2 structural proteins. Inhibition of these proteases may possibly reduce the viral load and infection on the host by hampering the synthesis of new viruses, thus promoting a better outcome. In silico assays consisting in the modeling of the ligand sitagliptin and evaluation of its capacity to interact with 3CLpro and PLpro through the prediction of the ligand bioactivity, molecular docking, overlapping of crystal structures, and molecular dynamic simulations were conducted. The experiments indicate that sitagliptin can interact and bind to both targets. However, this interaction seems to be stronger and more stable to 3CLpro (ΔG = −7.8 kcal mol−1), when compared to PLpro (ΔG = −7.5 kcal mol−1). This study suggests that sitagliptin may be suitable to treat COVID-19 patients, beyond its common use as an anti-diabetic medication. In vivo studies may further support this hypothesis.

1 January 2020 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
CLChristiane Bezerra Rocha Liberato
Christiane Bezerra Rocha Liberato
NONatália Bitar da Cunha Olegario
Natália Bitar da Cunha Olegario
VFVirginia Oliveira Fernandes
Virginia Oliveira Fernandes
AMAna Paula Dias Rangel Montenegro
Ana Paula Dias Rangel Montenegro
GLGrayce Lima
Grayce Lima
Renan Magalhães Montenegro JuniorRenan Magalhães Montenegro Junior
Renan Magalhães Montenegro Junior
Purpose: Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by the absence of functional adipocytes resulting in ectopic lipid storage, metabolic disorders and early cardiovascular disease. Two-dimensional speckle-tracking (2D-STE) allows the detection of early abnormalities in myocardial function. We aimed to evaluate myocardial deformation in a large sample of CGL patients using 2D-STE. Patients and Methods: A cross-sectional study of 22 patients with CGL and 22 healthy subjects, matched for sex and age, was conducted from 2013 to 2018. All participants had undergone standard conventional echocardiography (ECHO) and 2D-STE. Determination of blood glucose, lipids, insulin, and leptin were performed in all CGL patients. Results: In the CGL group the mean age was 14.6± 10.7 years where 68.2% (n=15) were younger than 18 years old. All the patients had hypoleptinemia, 95.4% (21/22) low HDL-c, 86.4% (19/22) hypertriglyceridemia, 68.2% (15/22) diabetes, 50% (11/22) hepatic steatosis, 41% (9/22) insulin resistance, 41% (9/22) hypercholesterolemia, and 18.2% (4/22) hypertension. ECHO showed that 36.6% (8/22) of CGL patients presented diastolic dysfunction, 31.8% (7/22) left ventricular hypertrophy (LVH), 27.3% (6/22) increased left atrial volume index (LAVI), and 18.2% (4/22) increased left ventricular systolic diameter (LVDS) but normal ejection fraction (EF), whether using 2D-STE, 68.2% (15/22) of CGL patients showed abnormal global longitudinal strain (GLS) (p< 0.01), and in almost LV segments. Positive association between abnormal GLS and A1c (r=0.57, p=0.005), glucose (r=0.5, p=0.018) and basal insulin (r= 0.69, p= 0.024), and negative association with leptin (r = − 0.51, p = 0.005) were found in these patients. Conclusion: The 2D-STE revealed precocious left ventricular systolic dysfunction in a young CGL population with normal systolic function by ECHO. Early exposure to common metabolic abnormalities as insulin resistance, hyperglycemia, and hypoleptinemia must be involved in myocardial damage in these patients.

4 September 2024 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
VVVictor Rezende Veras
Victor Rezende Veras
GLGrayce Lima
Grayce Lima
IMIvana da Ponte Melo
Ivana da Ponte Melo
VFVirginia Oliveira Fernandes
Virginia Oliveira Fernandes
FLFabia Karine de Moura Lopes
Fabia Karine de Moura Lopes
Renan Magalhães Montenegro JuniorRenan Magalhães Montenegro Junior
Renan Magalhães Montenegro Junior
Background: Familial Partial Lipodystrophy (FPLD) is a disease with wide clinical and genetic variation, with seven different subtypes described. Until genetic testing becomes feasible in clinical practice, non-invasive tools are used to evaluate body composition in lipodystrophic patients. This study aimed to analyze the different anthropometric parameters used for screening and diagnosis of FPLD, such as thigh skinfold thickness (TS), Köb index (Köbi), leg fat percentage (LFP), fat mass ratio (FMR) and leg-to-total fat mass ratio in grams (LTR), by dual-energy X-ray absorptiometry, focusing on determining cutoff points for TS and LFP within a Brazilian population. Methods: Thirty-seven patients with FPLD and seventy-four healthy controls matched for body mass index, sex and age were studied. Data were collected through medical record review after signing informed consent. All participants had body fat distribution evaluated by skinfolds and DXA measures. Fasting blood samples were collected to evaluate glycemic and lipid profiles. Genetic studies were carried out on all patients. Two groups were categorized based on genetic testing and/or anthropometric characteristics: FPLD+ (positive genetic test) and FPLD1 (negative genetic testing, but positive clinical/anthropometric criteria for FPLD). Results: Eighteen (48.6%) patients were classified as FPLD+, and 19 (51.4%) as FPLD1. Unlike what is described in the literature, the LMNA variant in codon 582 was the most common. Among the main diagnostic parameters of FPLD, a statistical difference was observed between the groups for, Köbi, TS, LFP, FMR, and LTR. A cutoff point of 20 mm for TS in FPLD women was found, which is lower than the value classically described in the literature for the diagnosis of FPLD. Additionally, an LFP < 29.6% appears to be a useful tool to aid in the diagnosis of these women. Conclusion: Combining anthropometric measurements to assess body fat distribution can lead to a more accurate diagnosis of FPLD. This study suggests new cutoff points for thigh skinfold and leg fat percentage in women with suspected FPLD in Brazil. Further studies are needed to confirm these findings.

13 June 2021 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MMMayara Ponte Madeira
Mayara Ponte Madeira
EFErika Freire
Erika Freire
VFVirginia Oliveira Fernandes
Virginia Oliveira Fernandes
GLGrayce Lima
Grayce Lima
IMIvana da Ponte Melo
Ivana da Ponte Melo
B(Brazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO)
Brazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO)
Background: A new strain of human coronavirus (HCoV) spread rapidly around the world. Diabetes and obesity are associated with a worse prognosis in these patients. Congenital Generalized Lipodystrophy (CGL) patients generally have poorly controlled diabetes and require extremely high doses of insulin. There is no documentation in the literature of cases of COVID in CGL patients. Thus, we aimed to evaluate the prevalence of SARS-CoV-2 infection in CGL patients, and the association of their clinical and metabolic characteristics and outcomes. Methods: This is a cross-sectional study carried out between July and October 2020. Clinical data collected were respiratory or other flu-like symptoms, need of hospitalization in the last three months, CGL comorbidities, and medications in use. Cholesterol, triglycerides, glycohemoglobin A1c levels, anti-SARS-CoV-2 antibodies and nasopharyngeal swab for RT-qPCR were also obtained in all CGL patients. Mann-Whitney U test was used to analyze the characteristics of the participants, verifying the non-adherence of the data to the Gaussian distribution. In investigating the association between categorical variables, we used Pearson's chi-square test and Fisher's exact test. A significance level of 5% was adopted. Results: Twenty-two CGL patients were assessed. Eight subjects (36.4%) had reactive anti-SARS-CoV-2 antibodies. Only one of these, also presented detectable RT-qPCR. Five individuals (62.5%) were women, median age of 13.5 years (1 to 37). Symptoms like fever, malaise, nausea, diarrhea and chest pain were present, and all asymptomatic patients were children. All subjects had inadequate metabolic control, with no difference between groups. Among positive individuals there was no difference between those with AGPAT2 (75%) and BSCL2 gene mutations (25%) (p > 0.05). No patient needed hospitalization or died. Conclusions: We described a high prevalence of SARS-CoV-2 infection in CGL patients with a good outcome in all of them. These findings suggest that at least young CGL patients infected by SARS-COV-2 are not at higher risk of poor outcome, despite known severe metabolic comorbidities.

10 October 2025 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
GLGrayce Lima
Grayce Lima
FLFabia Karine de Moura Lopes
Fabia Karine de Moura Lopes
JAJessica Silveira Araújo
Jessica Silveira Araújo
NBNatália Prado Boris
Natália Prado Boris
VFVirginia Oliveira Fernandes
Virginia Oliveira Fernandes
Renan Magalhães Montenegro JuniorRenan Magalhães Montenegro Junior
Renan Magalhães Montenegro Junior
Background: Lipodystrophy syndromes (LS) are characterized by reduced body fat and associated metabolic complications, such as insulin resistance and diabetes. The diagnosis of LS can be challenging in clinical settings. Skinfold measurement and body composition assessment using DEXA are commonly used for screening and diagnosis. This study aimed to identify alternative easy-to-use body composition parameters for diagnosing LS in clinical settings. Methods: This cross-sectional study included patients with genetically confirmed congenital generalized lipodystrophy (CGL) and familial partial lipodystrophy (FPL), with 62 matched healthy controls. Comprehensive data, including medical history, body composition, laboratory measurements, and imaging parameters, were collected. The receiver operating characteristic (ROC) curve was constructed using genetic test results, the gold standard for diagnosing genetic lipodystrophy, as the reference, and the sensitivity and specificity of calf skinfold measurements were measured with those of the genetic tests. Results: We included 62 patients with a mean age of 32 ± 18 (2–68) years, of whom 69.3% were women. The prevalence of diabetes mellitus (70%) and hypertriglyceridemia (83%) were also high. All body composition parameters significantly differed, except for calf skinfold measurements, which were similar between the CGL and FPL patients (p = 0.270). The ROC curve analysis identified a new cutoff point for calf skinfold measurement of <8 mm, with high diagnostic accuracy. Conclusions: This study identified calf skinfold measurements <8 mm as an accurate diagnostic tool for CGL and FPL. Notably, clinical accessibility to calf skinfold will favor its widespread use, standardization, and inclusion in physical examination protocols, improving lipodystrophy detection and diagnosis.